Correlation of Parathormone and Bone Disorders in Black Adult Hemodialysis Patients in the Public Sector in Abidjan, Côte d’Ivoire
Eric Sagou Yayo *
Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, BP V34, Abidjan, Côte d'Ivoire.
Kadio Morel Kouacou
Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, BP V34, Abidjan, Côte d'Ivoire.
Carine Mireille Yao-Yapo
Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, BP V34, Abidjan, Côte d'Ivoire.
Yékayo Bénédicte Koné-Dakouri
Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, BP V34, Abidjan, Côte d'Ivoire.
Jean Louis Konan
Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, BP V34, Abidjan, Côte d'Ivoire.
Akissi Joelle Koffi
Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, BP V34, Abidjan, Côte d'Ivoire.
Hubert Yao
Nephrology Department of CHU Treichville, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire.
Ake-Edjeme Angèle
Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, BP V34, Abidjan, Côte d'Ivoire.
Marie Laure Hauhouot-Attoungbré
Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, BP V34, Abidjan, Côte d'Ivoire.
Appolinaire Gnionsahe
Nephrology Department, Faculty of Medicine, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire.
Dagui Monnet
Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, BP V34, Abidjan, Côte d'Ivoire.
*Author to whom correspondence should be addressed.
Abstract
Introduction: The progression of chronic kidney disease (CKD) is characterized by several complications, including disorders of phosphocalcium metabolism characterized by secondary hyperparathyroidism. For this reason, major international recommendations call for at least annual parathyroid hormone (PTH) determinations in patients suffering from CKD, particularly in the terminal phase.
This study aims to explore parathyroid hormone status and bone disorders in adult hemodialysis patients in the public sector of Abidjan, West Africa.
Materials and Methods: This was a cross-sectional study of 100 end-stage chronic renal failure patients treated by hemodialysis. Parathyroid hormone (PTH) was determined by ELFA enzyme-linked immunosorbent assay on the VIDAS® platform. PTH values were interpreted in relation to the range of 2 to 9 times the upper normal limit in healthy subjects, in line with current KDIGO recommendations, and compared with clinical bone complications.
Results: Median PTH level was 315.95 (123.37-725.22) pg/mL. 48% of patients had PTH levels above the recommended threshold. Of these, almost half had no bone complications.
Conclusion: The present study did not show a direct relationship between bone complications and the PTH thresholds recommended by KDIGO. This result allows us to envisage a possible inadequacy of the cut-off values for these black African dialysis patients, through subsequent studies.
Keywords: Parathyroid hormone, black, hemodialized, bone disorders